Moderna, Inc. (MRNA) AI Stock Analysis

Moderna, Inc., based in Cambridge, Massachusetts, specializes in messenger RNA (mRNA) therapeutics and vaccines across infectious diseases, immuno-oncology, rare diseases, cardiovascular conditions, and autoimmune diseases. Its portfolio features respiratory vaccines for COVID-19, flu, and respiratory syncytial virus, alongside latent vaccines for cytomegalovirus and Epstein-Barr virus. Moderna is also advancing public health vaccines for Zika and Nipah, cancer vaccines including personalized and KRAS candidates, systemic intracellular treatments, and inhaled pulmonary therapies. Founded in 2010, the company maintains strategic biopharmaceutical partnerships with AstraZeneca PLC, Merck & Co., Vertex Pharmaceuticals, and the Bill & Melinda Gates Foundation.

Moderna experienced significant top-line contraction after FY2022. Revenue fell 63.7% in FY2023 to $6.85B, 53.3% in FY2024 to $3.20B, and 39.2% in FY2025 to $1.94B. Operating margins deteriorated over this period, shifting from 49.9% in FY2022 to -158.1% in FY2025, alongside net margins of -145.2% and net income of -$2.82B. R&D expense was $3.13B in FY2025, while free cash flow stood at -$2.06B. For the trailing twelve months ending June 30, 2026, revenue totaled $2.23B with an operating margin of -557.9% and EPS of -$7.98. In the latest quarter, quarterly revenue grew 2.1% year-over-year, while quarterly earnings dropped 85.1%.

As of June 30, 2026, Moderna held $5.14B in cash and short-term investments against total debt of $1.29B, yielding net cash of $3.85B. Shareholders' equity was $6.76B against total assets of $10.96B, reflecting a debt-to-equity ratio of 0.19 and a current ratio of 2.29. Operating cash flow in FY2025 was -$1.87B, and capital expenditures totaled $192.0M. Additionally, Moderna's share count declined 8.1% over the past 5 years.

MRNA trades at a forward P/E of 23.0x, above 19.7x for the median of its Nasdaq-100 Healthcare peers. Its price-to-sales multiple of 39.1x also trades at a substantial premium to the peer median of 6.5x, while EV/EBITDA stands at 4.6x compared to 24.5x for peers. Over the past year, Moderna delivered a 703.3% return against a 16.8% return for the S&P 500 (SPY). Over a 5-year period, MRNA fell 32.8% while the S&P 500 gained 83.0%.

Wall Street analysts hold 4 Strong Buy, 1 Buy, 14 Hold, 2 Sell, and 2 Strong Sell ratings on Moderna. The mean price target of $123.61 sits 43.3% below the last close of $218.01. For the fiscal year ending December 31, 2026, consensus calls for an EPS of -$8.38 on revenue of $2.10B. For the next fiscal year, 20 analysts project revenue of $2.44B and an EPS of -$4.78. Moderna beat EPS estimates in 2 of the last 4 quarters, with next earnings scheduled for November 6, 2026.

This page is an AI-written research summary of Moderna, Inc. (MRNA). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: MRNA income statement, MRNA balance sheet, MRNA key metrics, MRNA analyst forecast, MRNA chart. See the MRNA stock overview for the latest quote and news.